Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado-Joseph disease).
Freeman
William
W
Wszolek
Zbigniew
Z
D000328:Adult; D000067699:Ataxin-3; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017827:Machado-Joseph Disease / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D009128:Muscle Spasticity / Q000209:etiology*; D018482:Muscle, Skeletal; D009419:Nerve Tissue Proteins / Q000235:genetics; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009687:Nuclear Proteins; D017354:Point Mutation / Q000235:genetics; D012097:Repressor Proteins
D009419:Nerve Tissue Proteins; D009465:Neuromuscular Agents; D009687:Nuclear Proteins; D012097:Repressor Proteins; C092341:ATXN3 protein, human; D000067699:Ataxin-3; D019274:Botulinum Toxins, Type A